Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Seminars in Immunopathology
Published in: Seminars in Immunopathology 3/2008

01-07-2008 | Review

NOX enzymes and diabetic complications

Authors: Tomoko Kakehi, Chihiro Yabe-Nishimura

Published in: Seminars in Immunopathology | Issue 3/2008

Login to get access

Abstract

Several molecular mechanisms have been identified that mediate the tissue-damaging effects of hyperglycemia. These are increased flux through the polyol and hexosamine pathways, increased formation of advanced glycation end products, activation of protein kinase C, and augmented generation of reactive oxygen species (ROS). Increased production of ROS not only causes cellular damage but also activates the signal transduction cascade that activates specific target genes. Based on recent experimental data, it is now accepted that increased NADPH oxidase activity in tissues vulnerable to hyperglycemia takes place downstream of the advanced glycation end products and protein kinase C pathways, two of the primary mechanisms involved in the pathogenesis of diabetic complications. Thus, compounds that suppress NADPH oxidase activity may offer therapeutic benefits to ameliorate diabetic complications, highlighting the significance of NADPH oxidase as a new therapeutic target.
Literature
1.
Yabe-Nishimura C (1998) Aldose reductase in glucose toxicity: a potential target for the prevention of diabetic complications. Pharmacol Rev 50:21–33PubMed
2.
Sato Y, Hotta N, Sakamoto N et al (1979) Lipid peroxide level in plasma of diabetic patients. Biochem Med 21:104–107PubMedCrossRef
3.
Brownlee M, Cerami A, Vlassara H (1988) Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 318:1315–1321PubMed
4.
Lee TS, Saltsman KA, Ohashi H et al (1989) Activation of protein kinase C by elevation of glucose concentration: proposal for a mechanism in the development of diabetic vascular complications. Proc Natl Acad Sci USA 86:5141–5145PubMedCrossRef
5.
Kolm-Litty V, Sauer U, Nerlich A et al (1998) High glucose-induced transforming growth factor beta1 production is mediated by the hexosamine pathway in porcine glomerular mesangial cells. J Clin Invest 101:160–169PubMedCrossRef
6.
Brownlee M (2005) The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54:1615–1625PubMedCrossRef
7.
Dunlop M (2000) Aldose reductase and the role of the polyol pathway in diabetic nephropathy. Kidney Int Suppl 58:3–12CrossRef
8.
Mullarkey CJ, Edelstein D, Brownlee M (1990) Free radical generation by early glycation products: a mechanism for accelerated atherogenesis in diabetes. Biochem Biophys Res Commun 173:932–939PubMedCrossRef
9.
Inoguchi T, Li P, Umeda F et al (2000) High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes 49:1939–1945PubMedCrossRef
10.
Guzik TJ, West NE, Black E et al (2000) Vascular superoxide production by NAD(P)H oxidase: association with endothelial dysfunction and clinical risk factors. Circ Res 86:E85–E90PubMed
11.
Guzik TJ, Mussa S, Gastaldi D et al (2002) Mechanisms of increased vascular superoxide production in human diabetes mellitus: role of NAD(P)H oxidase and endothelial nitric oxide synthase. Circulation 105:1656–1662PubMedCrossRef
12.
13.
Lassegue B, Clempus RE (2003) Vascular NAD(P)H oxidases: specific features, expression, and regulation. Am J Physiol Regul Integr Comp Physiol 285:R277–R297PubMed
14.
Miyata K, Rahman M, Shokoji T et al (2005) Aldosterone stimulates reactive oxygen species production through activation of NADPH oxidase in rat mesangial cells. J Am Soc Nephrol 16:2906–2912PubMedCrossRef
15.
Bedard K, Krause KH (2007) The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev 87:245–313PubMedCrossRef
16.
Uusitupa MI, Niskanen LK, Siitonen O et al (1990) 5-year incidence of atherosclerotic vascular disease in relation to general risk factors, insulin level, and abnormalities in lipoprotein composition in non-insulin-dependent diabetic and nondiabetic subjects. Circulation 82:27–36PubMed
17.
Heinloth A, Heermeier K, Raff U et al (2000) Stimulation of NADPH oxidase by oxidized low-density lipoprotein induces proliferation of human vascular endothelial cells. J Am Soc Nephrol 11:1819–1825PubMed
18.
Wautier MP, Chappey O, Corda S et al (2001) Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab 280:E685–E694PubMed
19.
Basta G, Schmidt AM, De Caterina R (2004) Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc Res 63:582–592PubMedCrossRef
20.
Hathaway CA, Heistad DD, Piegors DJ et al (2002) Regression of atherosclerosis in monkeys reduces vascular superoxide levels. Circ Res 90:277–283PubMedCrossRef
21.
Zhou MS, Hernandez Schulman I, Pagano PJ et al (2005) Reduced NAD(P)H oxidase in low renin hypertension: link among angiotensin II, atherogenesis, and blood pressure. Hypertension 47:81–86PubMedCrossRef
22.
Sorescu D, Weiss D, Lassegue B et al (2002) Superoxide production and expression of nox family proteins in human atherosclerosis. Circulation 105:1429–1435PubMedCrossRef
23.
Stoll LL, McCormick ML, Denning GM et al (2004) Antioxidant effects of statins. Drugs Today (Barc) 40:975–990CrossRef
24.
Kirk EA, Dinauer MC, Rosen H et al (2000) Impaired superoxide production due to a deficiency in phagocyte NADPH oxidase fails to inhibit atherosclerosis in mice. Arterioscler Thromb Vasc Biol 20:1529–1535PubMed
25.
Cogan DG, Toussaint D, Kuwabara T (1961) Retinal vascular patterns. IV. Diabetic retinopathy. Arch Ophthalmol 66:366–378PubMed
26.
Cacicedo JM, Benjachareowong S, Chou E et al (2005) Palmitate-induced apoptosis in cultured bovine retinal pericytes: roles of NAD(P)H oxidase, oxidant stress, and ceramide. Diabetes 54:1838–1845PubMedCrossRef
27.
Raicu A, Raicu M, Simionescu M (2005) Expression of functionally phagocyte-type NAD(P)H oxidase in pericytes: effect of angiotensin II and high glucose. Biol Cell 97:723–734PubMedCrossRef
28.
Suzuma I, Murakami T, Suzuma K et al (2006) Cyclic stretch-induced reactive oxygen species generation enhances apoptosis in retinal pericytes through c-Jun NH2-terminal kinase activation. Hypertension 49:347–354PubMedCrossRef
29.
Li L, Renier G (2006) Activation of nicotinamide adenine dinucleotide phosphate (reduced form) oxidase by advanced glycation end products links oxidative stress to altered retinal vascular endothelial growth factor expression. Metabolism 55:1516–1523PubMedCrossRef
30.
Abid MR, Spokes KC, Shih SC et al (2007) NADPH oxidase activity selectively modulates vascular endothelial growth factor signaling pathways. J Biol Chem 282:35373–35385PubMedCrossRef
31.
Goldblatt D, Butcher J, Thrasher AJ et al (1999) Chorioretinal lesions in patients and carriers of chronic granulomatous disease. J Pediatr 134:780–783PubMedCrossRef
32.
Kim SJ, Kim JG, Yu YS (2003) Chorioretinal lesions in patients with chronic granulomatous disease. Retina 23:360–365PubMedCrossRef
33.
Dawson DW, Volpert OV, Gillis P et al (1999) Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 285:245–248PubMedCrossRef
34.
Spranger J, Osterhoff M, Reimann M et al (2001) Loss of the antiangiogenic pigment epithelium-derived factor in patients with angiogenic eye disease. Diabetes 50:2641–2645PubMedCrossRef
35.
Yamagishi S, Nakamura K, Matsui T et al (2006) Pigment epithelium-derived factor inhibits advanced glycation end product-induced retinal vascular hyperpermeability by blocking reactive oxygen species-mediated vascular endothelial growth factor expression. J Biol Chem 281:20213–20220PubMedCrossRef
36.
Goldstein BJ, Mahadev K, Wu X (2004) Redox paradox: insulin action is facilitated by insulin-stimulated reactive oxygen species with multiple potential signaling targets. Diabetes 54:311–321CrossRef
37.
Wolf G, Ziyadeh FN (1999) Molecular mechanisms of diabetic renal hypertrophy. Kidney Int 56:393–405PubMedCrossRef
38.
Ziyadeh FN (1993) The extracellular matrix in diabetic nephropathy. Am J Kidney Dis 22:736–744PubMed
39.
Phillips AO (2003) The role of renal proximal tubular cells in diabetic nephropathy. Curr Diab Rep 3:491–496PubMedCrossRef
40.
Ziyadeh FN, Sharma K, Ericksen M et al (1994) Stimulation of collagen gene expression and protein synthesis in murine mesangial cells by high glucose is mediated by autocrine activation of transforming growth factor-beta. J Clin Invest 93:536–542PubMedCrossRef
41.
Oh JH, Ha H, Yu MR et al (1998) Sequential effects of high glucose on mesangial cell transforming growth factor-beta 1 and fibronectin synthesis. Kidney Int 54:1872–1878PubMedCrossRef
42.
Lee HB, Yu MR, Yang Y et al (2003) Reactive oxygen species-regulated signaling pathways in diabetic nephropathy. J Am Soc Nephrol 14:241S–245SCrossRef
43.
Iglesias-De La Cruz MC, Ruiz-Torres P, Alcami J et al (2001) Hydrogen peroxide increases extracellular matrix mRNA through TGF-beta in human mesangial cells. Kidney Int 59:87–95PubMedCrossRef
44.
Ha H, Lee HB (2000) Reactive oxygen species as glucose signaling molecules in mesangial cells cultured under high glucose. Kidney Int Suppl 58:19–25CrossRef
45.
Ha H, Lee SH, Kim KH (1997) Effects of rebamipide in a model of experimental diabetes and on the synthesis of transforming growth factor-beta and fibronectin, and lipid peroxidation induced by high glucose in cultured mesangial cells. J Pharmacol Exp Ther 281:1457–1462PubMed
46.
Lafon C, Mathieu C, Guerrin M et al (1996) Transforming growth factor beta 1-induced apoptosis in human ovarian carcinoma cells: protection by the antioxidant N-acetylcysteine and bcl-2. Cell Growth Differ 7:1095–1104PubMed
47.
Hong YH, Peng HB, La Fata V et al (1997) Hydrogen peroxide-mediated transcriptional induction of macrophage colony-stimulating factor by TGF-beta1. J Immunol 159:2418–2423PubMed
48.
Koo HY, Shin I, Lee ZW et al (1999) Roles of RhoA and phospholipase A2 in the elevation of intracellular H2O2 by transforming growth factor-beta in Swiss 3T3 fibroblasts. Cell Signal 11:677–683PubMedCrossRef
49.
Junn E, Lee KN, Ju HR et al (2000) Requirement of hydrogen peroxide generation in TGF-beta 1 signal transduction in human lung fibroblast cells: involvement of hydrogen peroxide and Ca2+in TGF-beta 1-induced IL-6 expression. J Immunol 165:2190–2197PubMed
50.
Chiu C, Maddock DA, Zhang Q et al (2001) TGF-beta-induced p38 activation is mediated by Rac1-regulated generation of reactive oxygen species in cultured human keratinocytes. Int J Mol Med 8:251–255PubMed
51.
Herrera B, Alvarez AM, Sanchez A et al (2001) Reactive oxygen species (ROS) mediates the mitochondrial-dependent apoptosis induced by transforming growth factor (beta) in fetal hepatocytes. Faseb J 15:741–751PubMedCrossRef
52.
Jaimes EA, Galceran JM, Raij L (1998) Angiotensin II induces superoxide anion production by mesangial cells. Kidney Int 54:775–784PubMedCrossRef
53.
Kagami S, Border WA, Miller DE et al (1994) Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J Clin Invest 93:2431–2437PubMedCrossRef
54.
55.
Schnaper HW (1995) Balance between matrix synthesis and degradation: a determinant of glomerulosclerosis. Pediatr Nephrol 9:104–111PubMedCrossRef
56.
Stetler-Stevenson WG (1996) Dynamics of matrix turnover during pathologic remodeling of the extracellular matrix. Am J Pathol 148:1345–1350PubMed
57.
Yang ZZ, Zou AP (2003) Homocysteine enhances TIMP-1 expression and cell proliferation associated with NADH oxidase in rat mesangial cells. Kidney Int 63:1012–1020PubMedCrossRef
58.
Lee EA, Seo JY, Jiang Z et al (2005) Reactive oxygen species mediate high glucose-induced plasminogen activator inhibitor-1 up-regulation in mesangial cells and in diabetic kidney. Kidney Int 67:1762–1771PubMedCrossRef
59.
Jiang Z, Seo JY, Ha H et al (2003) Reactive oxygen species mediate TGF-beta1-induced plasminogen activator inhibitor-1 upregulation in mesangial cells. Biochem Biophys Res Commun 309:961–966PubMedCrossRef
60.
Kumar D, Robertson S, Burns KD (2004) Evidence of apoptosis in human diabetic kidney. Mol Cell Biochem 259:67–70PubMedCrossRef
61.
Pesce C, Menini S, Pricci F et al (2002) Glomerular cell replication and cell loss through apoptosis in experimental diabetes mellitus. Nephron 90:484–488PubMedCrossRef
62.
Verzola D, Bertolotto MB, Villaggio B et al (2004) Oxidative stress mediates apoptotic changes induced by hyperglycemia in human tubular kidney cells. J Am Soc Nephrol 15(Suppl 1):85S–87SCrossRef
63.
Brezniceanu ML, Liu F, Wei CC et al (2007) Catalase overexpression attenuates angiotensinogen expression and apoptosis in diabetic mice. Kidney Int 71:912–923PubMedCrossRef
64.
Petermann AT, Krofft R, Blonski M et al (2003) Podocytes that detach in experimental membranous nephropathy are viable. Kidney Int 64:1222–1231PubMedCrossRef
65.
Susztak K, Raff AC, Schiffer M et al (2006) Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes 55:225–233PubMedCrossRef
66.
Lodha S, Dani D, Mehta R et al (2002) Angiotensin II-induced mesangial cell apoptosis: role of oxidative stress. Mol Med 8:830–840PubMed
67.
Chow F, Ozols E, Nikolic-Paterson DJ et al (2004) Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state and progressive renal injury. Kidney Int 65:116–128PubMedCrossRef
68.
Satriano JA, Shuldiner M, Hora K et al (1993) Oxygen radicals as second messengers for expression of the monocyte chemoattractant protein, JE/MCP-1, and the monocyte colony-stimulating factor, CSF-1, in response to tumor necrosis factor-alpha and immunoglobulin G. Evidence for involvement of reduced nicotinamide adenine dinucleotide phosphate (NADPH)-dependent oxidase. J Clin Invest 92:1564–1571PubMedCrossRef
69.
Ha H, Yu MR, Choi YJ et al (2002) Role of high glucose-induced nuclear factor-kappaB activation in monocyte chemoattractant protein-1 expression by mesangial cells. J Am Soc Nephrol 13:894–902PubMed
70.
Cheng J, Diaz Encarnacion MM, Warner GM et al (2005) TGF-beta1 stimulates monocyte chemoattractant protein-1 expression in mesangial cells through a phosphodiesterase isoenzyme 4-dependent process. Am J Physiol Cell Physiol 289:C959–C970PubMedCrossRef
71.
Gu L, Hagiwara S, Fan Q et al (2005) Role of receptor for advanced glycation end-products and signalling events in advanced glycation end-product-induced monocyte chemoattractant protein-1 expression in differentiated mouse podocytes. Nephrol Dial Transplant 21:299–313PubMedCrossRef
72.
Gauer S, Hauser IA, Obermuller N et al (2008) Synergistic induction of osteopontin by aldosterone and inflammatory cytokines in mesangial cells. J Cell Biochem 103:615–623PubMedCrossRef
73.
Nian M, Lee P, Khaper N et al (2004) Inflammatory cytokines and postmyocardial infarction remodeling. Circ Res 94:1543–1553PubMedCrossRef
74.
Fujihara CK, Padilha RM, Zatz R (1992) Glomerular abnormalities in long-term experimental diabetes. Role of hemodynamic and nonhemodynamic factors and effects of antihypertensive therapy. Diabetes 41:286–293PubMedCrossRef
75.
Schnackenberg CG, Welch WJ, Wilcox CS (1998) Normalization of blood pressure and renal vascular resistance in SHR with a membrane-permeable superoxide dismutase mimetic: role of nitric oxide. Hypertension 32:59–64PubMed
76.
Schnackenberg CG, Welch WJ, Wilcox CS (2000) TP receptor-mediated vasoconstriction in microperfused afferent arterioles: roles of O(2)(−) and NO. Am J Physiol Renal Physiol 279:F302–F308PubMed
77.
Ortiz PA, Garvin JL (2002) Interaction of O(2)(−) and NO in the thick ascending limb. Hypertension 39:591–596PubMedCrossRef
78.
Li N, Yi FX, Spurrier JL et al (2002) Production of superoxide through NADH oxidase in thick ascending limb of Henle’s loop in rat kidney. Am J Physiol Renal Physiol 282:F1111–1119PubMed
79.
Zou AP, Li N, Cowley AW Jr (2001) Production and actions of superoxide in the renal medulla. Hypertension 37:547–553PubMed
80.
81.
Geiszt M, Kopp JB, Varnai P et al (2000) Identification of renox, an NAD(P)H oxidase in kidney. Proc Natl Acad Sci USA 97:8010–8014PubMedCrossRef
82.
Shiose A, Kuroda J, Tsuruya K et al (2001) A novel superoxide-producing NAD(P)H oxidase in kidney. J Biol Chem 276:1417–1423PubMedCrossRef
83.
Chabrashvili T, Tojo A, Onozato ML et al (2002) Expression and cellular localization of classic NADPH oxidase subunits in the spontaneously hypertensive rat kidney. Hypertension 39:269–274PubMedCrossRef
84.
Etoh T, Inoguchi T, Kakimoto M et al (2003) Increased expression of NAD(P)H oxidase subunits, NOX4 and p22phox, in the kidney of streptozotocin-induced diabetic rats and its reversibity by interventive insulin treatment. Diabetologia 46:1428–1437PubMedCrossRef
85.
Gorin Y, Ricono JM, Kim NH et al (2003) Nox4 mediates angiotensin II-induced activation of Akt/protein kinase B in mesangial cells. Am J Physiol Renal Physiol 285:F219–F229PubMed
86.
Ricono Y, Ricono JM, Wagner B et al (2004) Angiotensin II-induced ERK1/ERK2 activation and protein synthesis are redox-dependent in glomerular mesangial cells. Biochem J 381:231–239PubMedCrossRef
87.
Fujii M, Inoguchi T, Maeda Y et al (2007) Pitavastatin ameliorates albuminuria and renal mesangial expansion by downregulating NOX4 in db/db mice. Kidney Int 72:473–480PubMedCrossRef
88.
Gorin Y, Block K, Hernandez J et al (2005) Nox4 NAD(P)H oxidase mediates hypertrophy and fibronectin expression in the diabetic kidney. J Biol Chem 280:39616–39626PubMedCrossRef
89.
Chen G, Adeyemo AA, Zhou J et al (2007) A genome-wide search for linkage to renal function phenotypes in West Africans with type 2 diabetes. Am J Kidney Dis 49:394–400PubMedCrossRef
90.
Matsuno K, Yamada H, Iwata K et al (2005) Nox1 is involved in angiotensin II-mediated hypertension: a study in Nox1-deficient mice. Circulation 112:2677–2685PubMedCrossRef
91.
Dikalova A, Clempus R, Lassegue B et al (2005) Nox1 overexpression potentiates angiotensin II-induced hypertension and vascular smooth muscle hypertrophy in transgenic mice. Circulation 112:2668–2676PubMedCrossRef
92.
Gavazzi G, Banfi B, Deffert C et al (2006) Decreased blood pressure in NOX1-deficient mice. FEBS Lett 580:497–504PubMedCrossRef
93.
Chabrashvili T, Kitiyakara C, Blau J et al (2003) Effects of ANG II type 1 and 2 receptors on oxidative stress, renal NADPH oxidase, and SOD expression. Am J Physiol Regul Integr Comp Physiol 285:R117–R124PubMed
94.
Nishiyama A, Yoshizumi M, Hitomi H et al (2004) The SOD mimetic tempol ameliorates glomerular injury and reduces mitogen-activated protein kinase activity in Dahl salt-sensitive rats. J Am Soc Nephrol 15:306–315PubMedCrossRef
95.
Yogi A, Mercure C, Touyz J et al (2008) Renal redox-sensitive signaling, but not blood pressure, is attenuated by Nox1 knockout in angiotensin II-dependent chronic hypertension. Hypertension 51:500–506PubMedCrossRef
96.
Asaba K, Tojo A, Onozato ML et al (2005) Effects of NADPH oxidase inhibitor in diabetic nephropathy. Kidney Int 67:1890–1898PubMedCrossRef
97.
Ohshiro Y, Ma RC, Yasuda Y et al (2006) Reduction of diabetes-induced oxidative stress, fibrotic cytokine expression, and renal dysfunction in protein kinase Cbeta-null mice. Diabetes 55:3112–3120PubMedCrossRef
98.
Kitiyakara C, Chabrashvili T, Chen Y et al (2003) Salt intake, oxidative stress, and renal expression of NADPH oxidase and superoxide dismutase. J Am Soc Nephrol 14:2775–2782PubMedCrossRef
99.
Shi XY, Hou FF, Niu HX et al (2008) Advanced oxidation protein products promote inflammation in diabetic kidney through activation of renal nicotinamide adenine dinucleotide phosphate oxidase. Endocrinology 149:1829–1839PubMedCrossRef
100.
Zhan CD, Sindhu RK, Vaziri ND (2004) Up-regulation of kidney NAD(P)H oxidase and calcineurin in SHR: reversal by lifelong antioxidant supplementation. Kidney Int 65:219–227PubMedCrossRef
101.
Vaziri ND, Dicus M, Ho ND et al (2003) Oxidative stress and dysregulation of superoxide dismutase and NADPH oxidase in renal insufficiency. Kidney Int 63:179–185PubMedCrossRef
102.
Koya D, King GL (1998) Protein kinase C activation and the development of diabetic complications. Diabetes 47:859–866PubMedCrossRef
103.
Koya D, Jirousek MR, Lin YW et al (1997) Characterization of protein kinase C beta isoform activation on the gene expression of transforming growth factor-beta, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats. J Clin Invest 100:115–126PubMedCrossRef
104.
Ishii H, Jirousek MR, Koya D et al (1996) Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science 272:728–731PubMedCrossRef
105.
Korchak HM, Rossi MW, Kilpatrick LE (1998) Selective role for beta-protein kinase C in signaling for O−2 generation but not degranulation or adherence in differentiated HL60 cells. J Biol Chem 273:27292–27299PubMedCrossRef
106.
Dekker LV, Leitges M, Altschuler G et al (2000) Protein kinase C-beta contributes to NADPH oxidase activation in neutrophils. Biochem J 347(Pt 1):285–289PubMedCrossRef
107.
Fontayne A, Dang PM, Gougerot-Pocidalo MA et al (2002) Phosphorylation of p47phox sites by PKC alpha, beta II, delta, and zeta: effect on binding to p22phox and on NADPH oxidase activation. Biochemistry 41:7743–7750PubMedCrossRef
108.
Xia L, Wang H, Goldberg HJ et al (2006) Mesangial cell NADPH oxidase upregulation in high glucose is protein kinase C dependent and required for collagen IV expression. Am J Physiol Renal Physiol 290:F345–F356PubMedCrossRef
109.
Thallas-Bonke V, Thorpe SR, Coughlan MT et al (2007) Inhibition of NADPH oxidase prevents advanced glycation end product-mediated damage in diabetic nephropathy through a protein kinase C-alpha-dependent pathway. Diabetes 57:460–469PubMedCrossRef
110.
Wilmer WA, Dixon CL, Hebert C (2001) Chronic exposure of human mesangial cells to high glucose environments activates the p38 MAPK pathway. Kidney Int 60:858–871PubMedCrossRef
111.
Weigert C, Sauer U, Brodbeck K et al (2000) AP-1 proteins mediate hyperglycemia-induced activation of the human TGF-beta1 promoter in mesangial cells. J Am Soc Nephrol 11:2007–2016PubMed
112.
Pagtalunan ME, Miller PL, Jumping-Eagle S et al (1997) Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest 99:342–348PubMedCrossRef
113.
Greiber S, Munzel T, Kastner S et al (1998) NAD(P)H oxidase activity in cultured human podocytes: effects of adenosine triphosphate. Kidney Int 53:654–663PubMedCrossRef
114.
Schiffer M, Bitzer M, Roberts IS et al (2001) Apoptosis in podocytes induced by TGF-beta and Smad7. J Clin Invest 108:807–816PubMed
115.
Lewis EJ, Hunsicker LG, Bain RP et al (1993) The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329:1456–1462PubMedCrossRef
116.
Brenner BM, Cooper ME, de Zeeuw D et al (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861–869PubMedCrossRef
117.
Onozato ML, Tojo A, Goto A et al (2002) Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: effects of ACEI and ARB. Kidney Int 61:186–194PubMedCrossRef
118.
Yu HY, Inoguchi T, Nakayama M et al (2005) Statin attenuates high glucose-induced and angiotensin II-induced MAP kinase activity through inhibition of NAD(P)H oxidase activity in cultured mesangial cells. Med Chem 1:461–466PubMedCrossRef
119.
Vincent AM, Perrone L, Sullivan KA et al (2006) Receptor for advanced glycation end products activation injures primary sensory neurons via oxidative stress. Endocrinology 148:548–558PubMedCrossRef
120.
Coppey LJ, Gellett JS, Davidson EP et al (2003) Preventing superoxide formation in epineurial arterioles of the sciatic nerve from diabetic rats restores endothelium-dependent vasodilation. Free Radic Res 37:33–40PubMedCrossRef
121.
Modlinger P, Chabrashvili T, Gill PS et al (2005) RNA silencing in vivo reveals role of p22phox in rat angiotensin slow pressor response. Hypertension 47:238–244CrossRef
122.
Kitada M, Koya D, Sugimoto T et al (2003) Translocation of glomerular p47phox and p67phox by protein kinase C-beta activation is required for oxidative stress in diabetic nephropathy. Diabetes 52:2603–2614PubMedCrossRef
123.
Pleskova M, Beck KF, Behrens MH et al (2006) Nitric oxide down-regulates the expression of the catalytic NADPH oxidase subunit Nox1 in rat renal mesangial cells. Faseb J 20:139–141PubMed
124.
Williams KJ, Qiu G, Usui HK et al (2007) Decorin deficiency enhances progressive nephropathy in diabetic mice. Am J Pathol 171:1441–1450PubMedCrossRef
125.
Jones SA, Hancock JT, Jones OT et al (1995) The expression of NADPH oxidase components in human glomerular mesangial cells: detection of protein and mRNA for p47phox, p67phox, and p22phox. J Am Soc Nephrol 5:1483–1491PubMed
126.
Gojo A, Utsunomiya K, Taniguchi K et al (2007) The Rho-kinase inhibitor, fasudil, attenuates diabetic nephropathy in streptozotocin-induced diabetic rats. Eur J Pharmacol 568:242–247PubMedCrossRef
127.
Biswas SK, Peixoto EB, Souza DS et al (2008) Hypertension increases pro-oxidant generation and decreases antioxidant defense in the kidney in early diabetes. Am J Nephrol 28:133–142PubMedCrossRef
128.
Benter IF, Yousif MH, Dhaunsi GS et al (2008) Angiotensin-(1–7) prevents activation of NADPH oxidase and renal vascular dysfunction in diabetic hypertensive rats. Am J Nephrol 28:25–33PubMedCrossRef
129.
Nakamura N, Obayashi H, Fujii M et al (2000) Induction of aldose reductase in cultured human microvascular endothelial cells by advanced glycation end products. Free Radic Biol Med 29:17–25PubMedCrossRef
130.
Nishinaka T, Yabe-Nishimura C (2001) EGF receptor–ERK pathway is the major signaling pathway that mediates upregulation of aldose reductase expression under oxidative stress. Free Radic Biol Med 31:205–216PubMedCrossRef
Metadata
Title
NOX enzymes and diabetic complications
Authors
Tomoko Kakehi
Chihiro Yabe-Nishimura
Publication date
01-07-2008
Publisher
Springer-Verlag
Published in
Seminars in Immunopathology / Issue 3/2008
Print ISSN: 1863-2297
Electronic ISSN: 1863-2300
DOI
https://doi.org/10.1007/s00281-008-0122-7

Other articles of this Issue 3/2008

Seminars in Immunopathology 3/2008 Go to the issue

Review

Hyperinflammation in chronic granulomatous disease and anti-inflammatory role of the phagocyte NADPH oxidase

Review

Priming of the neutrophil NADPH oxidase activation: role of p47phox phosphorylation and NOX2 mobilization to the plasma membrane

Review

Nox enzymes in immune cells

Letter to the Editor

Remarks on the article Genetics and immunopathology of chronic granulomatous disease by Marie José Stasia and Xing Jun Li

Review

NOX enzymes as novel targets for drug development

Review

Nox enzymes and oxidative stress in the immunopathology of the gastrointestinal tract
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits